Locally Advanced Solid Tumor
46
16
21
10
Key Insights
Highlights
Success Rate
59% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
15.2%
7 terminated out of 46 trials
58.8%
-27.8% vs benchmark
2%
1 trials in Phase 3/4
40%
4 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 10 completed trials
Clinical Trials (46)
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
CD8 PET Imaging in Metastatic Solid Tumours